H.C. Wainwright Reiterates Buy Rating on Prime Medicine (PRME)

July 10, 2026 6:52 AM

H.C. Wainwright analyst Arthur He reiterated a Buy rating and $8.00 price target on Prime Medicine (NASDAQ: PRME).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found